Literature DB >> 17786356

The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa.

Xiaoyu Tian1, Gang Chen, Hui Xing, Danhui Weng, Yunhong Guo, Ding Ma.   

Abstract

The aim of this study was to clarify the function of non-homologous end-joining (NHEJ) in tumorigenesis and chemoresistance, and to explore the potential of DNA-PK as a target of reversal of chemoresistance and enhancing the sensitivity of cells to chemotherapeutic agents. Plasmid vectors pSIREN-Ku70shRNA and pSIREN-DNA-PKcssh-RNA, which coded small interfering RNA of Ku70 and DNA-PKcs, were constructed and transfected into human cervical cancer cell line HeLa. The relationship between the down-regulation of Ku70 or DNA-PKcs and tumor cell proliferation and the sensitivity of cells to chemotherapeutic agents were analyzed. Down-regulation of Ku70 and DNA-PKcs expression inhibited cell proliferation, and increased cell apoptosis in DDP-treated HeLa cells. DNA-PK might play an important role in drug resistance, and inhibition of the DNA-PK expression suppressed the growth of tumor cells and enhanced the sensitivity of cells to chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786356

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

2.  DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway.

Authors:  Yuan Fang; Zongtao Chai; Dansong Wang; Tiantao Kuang; Wenchuan Wu; Wenhui Lou
Journal:  Mol Cell Biochem       Date:  2014-10-28       Impact factor: 3.396

3.  Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63.

Authors:  Xin Li; Jiguang Tian; Qiyu Bo; Ka Li; Hongliang Wang; Ting Liu; Jianmin Li
Journal:  Tumour Biol       Date:  2015-06-25

4.  Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.

Authors:  P O Carminati; F S Donaires; M M Marques; E A Donadi; G A S Passos; E T Sakamoto-Hojo
Journal:  Mol Biol Rep       Date:  2013-11-12       Impact factor: 2.316

5.  DNA-dependent protein kinase catalytic subunit functions in metastasis and influences survival in advanced-stage laryngeal squamous cell carcinoma.

Authors:  Sha-Sha He; Yong Chen; Xiao-Ming Shen; Hong-Zhi Wang; Peng Sun; Jun Dong; Gui-Fang Guo; Ju-Gao Chen; Liang-Ping Xia; Pei-Li Hu; Hui-Juan Qiu; Shou-Sheng Liu; Yi-Xin Zhou; Wei Wang; Wei-Han Hu; Xiu-Yu Cai
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

6.  Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells.

Authors:  Long Cheng; Yuan-Yuan Liu; Pei-Hua Lu; Yi Peng; Qiang Yuan; Xin-Shi Gu; Yong Jin; Min-Bin Chen; Xu-Ming Bai
Journal:  Oncotarget       Date:  2017-04-25

7.  DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer.

Authors:  Manni Wang; Siyuan Chen; Yuquan Wei; Xiawei Wei
Journal:  Acta Pharm Sin B       Date:  2021-08-04       Impact factor: 11.413

8.  Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation.

Authors:  Ulrike Fischer; Stefanie Rheinheimer; Andrea Krempler; Markus Löbrich; Eckart Meese
Journal:  Int J Oncol       Date:  2013-05-13       Impact factor: 5.650

Review 9.  Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy.

Authors:  Daniela A Dungl; Elaina N Maginn; Euan A Stronach
Journal:  Front Oncol       Date:  2015-10-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.